Celtic PLC
28 August 2026
This announcement is a replacement of RNS 6825S which had an incorrect number of Deferred Shares, which has bene corrected in this announcement
CELTIC PLC
Issued share capital
As a result of the issue of 16,612 Ordinary Shares of 1p each under the Company's scrip dividend reinvestment scheme on 28 August 2026, Celtic plc's issued share capital as at 28 August 2026 was as follows:
95,139,731 Ordinary Shares of 1p each ("Ordinary Shares")
12,623,292 Convertible Preferred Ordinary Shares of 100p each ("CPO Shares")
15,467,623 Convertible Cumulative Preference Shares of 60p each ("CCP Shares")
706,616,416 Deferred Shares of 1p each
CCP Shares do not carry voting rights. Deferred Shares are not listed, are not transferable and carry no voting rights or substantive economic rights.
The above figures for Ordinary Shares and CPO Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in voting rights under the FCA's Disclosure Guidance and Transparency Rules.
The new Ordinary Shares of 1p each allotted under the scrip scheme have been issued at a notional price of 213.0p each.
Application has been made for the admission of the 16,612 new Ordinary Shares of 1p each arising from these conversions ("New Ordinary Shares") to trading on AIM. It is expected that dealings in these New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, will commence on 4 September 2026.
Enquiries:
Company
Joanne McNairn, Company Secretary 0141 551 4330
Canaccord Genuity Limited, Nominated Adviser
Simon Bridges, Andrew Potts 0207 523 8350
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.